MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. So what: If you purchased MoonLake common stockduring the Class Period you […]